TNFRSF8 and Hodgkins lymphoma: Another small clinical trial enrolled nine R/R CD30+ lymphoma patients [six with HL, three with anaplastic large cell lymphoma (ALCL)] who received a third-generation CAR-T cell therapy with both CD28 and CD137 as costimulatory domains following lymphodepletion with fludarabine and cyclophosphamide.